Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study
Main finding · Drug retention (adjusted)Result — go to the resultHazard ratio 0.38 95% CI 0.27–0.55Authors' conclusion
In EORA patients, IL-6i and JAKi had longer retention and less discontinuation due to ineffectiveness than TNFi.
Study context
- Population
- Patients with elderly-onset RA (onset at age 60 or over) in a Japanese multicentre observational registry, 2015–2022treatment courses in 572 patients
- Participants
- 835 patients
- Exposure
- Janus kinase inhibitors (JAKi), IL-6i and CTLA4-Ig vs TNF inhibitors (TNFi)
- TNFin = 314reference
- IL-6in = 175
- CTLA4-Ign = 228
- JAKin = 118
- Outcome
- Drug retention
Methodological detailsmulticentre, propensity score adjusted, observational registry
- Multicentre
- Propensity score adjusted
- Observational registry
Main finding
Drug retention (adjusted)
Hazard ratio
0.38
95% CI 0.27–0.55
P < 0.01
IL-6ivs TNFi
HR 0.38 (95% CI 0.27–0.55); P < 0.01
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Discontinuation due to lack of effectivenessJAKivs TNFi | 0.38 (0.22–0.66) | P < 0.01 | |
| Discontinuation due to lack of effectivenessIL-6ivs TNFi | 0.29 (0.19–0.46) | P < 0.01 | |
| 0.20.5125Hazard ratio (log scale) |
Discontinuation due to lack of effectiveness
- CTLA4-Ig had a similar HR to TNFi
Safety
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Discontinuation due to adverse events (adjusted)JAKivs TNFi | 2.86 (1.46–5.59) | P < 0.01 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study. Rheumatology (Oxford). Published 6 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →